Xconomy | San Diego - Business + Technology in the Exponential Economy

Abbott Labs Acquires Isis Diagnostics Unit for $215M
Isis Spinoff Ibis Biosciences, Looking at DNA of Infectious Bugs, Aims to Identify What They Are, Faster
Isis Subsidiary Receives Grants, Contracts Worth $8.4 Million
UK’s Enigma Looks to San Diego, Life Gets Sweeter for Senomyx, Arena Says Obesity Drug Is Not “Wimpy,” & More San Diego Life Sciences News
Sequenom Down Syndrome Results “Deliberately Doctored,” Says Partner Xenomics

Sequenom Settles Ibis Dispute

Sequenom, the San Diego-based maker of laboratory tools and diagnostics, said today in a regulatory filing it has agreed to accept a $1 million payment from Ibis Biosciences, a unit of Abbott Laboratories, to settle a patent infringement lawsuit. As part of the deal, Sequenom (NASDAQ: SQNM) has granted Ibis a non-exclusive license to three mass spectrometry-based patents. Abbott acquired Ibis, a spinoff from Carlsbad, CA-based Isis Pharmaceuticals, for $215 million in December.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: